On August 19th, according to the official website of the National Medical Products Administration, AstraZeneca's IL-5R alpha monoclonal antibody (benralizumab) has been approved for listing in China. This drug was first developed by Concord Kirin and later acquired and commercialized by AstraZeneca for the additional maintenance treatment of severe eosinophilic asthma patients aged 12 and above. In April of this year, IL-5R α monoclonal antibody was approved by the US FDA to expand its application to additional maintenance therapy for severe asthma patients with eosinophilic phenotype aged 6-11 years. In 2023, the global sales of this drug will reach 1.553 billion US dollars. (He Xinyi)